


Exatecan Intermediate 5

Cat. No.:	HY-43564		
CAS No.:	143655-70-3		
Molecular Formula:	C ₁₅ H ₁₇ FN ₂ O ₃		
Molecular Weight:	292.31		
Target:	Topoisomerase		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (85.53 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.4210 mL	17.1051 mL	34.2103 mL
	5 mM	0.6842 mL	3.4210 mL	6.8421 mL
	10 mM	0.3421 mL	1.7105 mL	3.4210 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.2 mg/mL (7.53 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.2 mg/mL (7.53 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.2 mg/mL (7.53 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Exatecan Intermediate 5 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC₅₀ value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 5 can be used to synthesize Antibody-Drug Conjugates (ADCs).

REFERENCES

[1]. Xu, et al. Preparation of exatecan intermediate and its application. China, CN115701419 A. 2023-02-10.

[2]. Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776-82.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA